Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional X-ray examinations, computed tomography (CT) and magnetic resonance imaging (MRI). Changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. At Lund University Hospital, a new imaging technique, diffusional variance decomposition (DIVIDE), has now been developed. With this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
150
Brain metastases radiation according to clinical practice.
Lund University Hospital
Lund, Sweden
RECRUITINGGrade of radiation sensitivity to brain metastasis.
Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy.
Grade of radiation sensitivity to brain metastasis.
Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 3 months after end of treatment.
Grade of radiation sensitivity to brain metastasis.
Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 6 months after end of treatment.
Early changes in the tumor during and after completion of radiation therapy.
Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy.
Early changes in the tumor during and after completion of radiation therapy.
Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 3 months after end of treatment.
Early changes in the tumor during and after completion of radiation therapy.
Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 6 months after end of treatment.
Changes linked to treatment responses.
Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy.
Changes linked to treatment responses.
Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 3 months after end of treatment.
Changes linked to treatment responses.
Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after 6 months after end of treatment.
Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
Time frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy.
Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy after 3 months after end of treatment.
Time frame: Is evaluated after 3 months after end of treatment.
Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after and 6 months after end of treatment.
Time frame: Is evaluated after 6 months after end of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.